ERBB2 and cancer: As a key example of the translational potential of these concepts, an ongoing Phase I clinical trial is recruiting patients with HER2-positive cancers to evaluate a combination of autologous HER2 CAR-T cells and intratumoral administration of CAdVEC, an oncolytic adenovirus.